Strong SA, Peto T, Bunce C, et al. - In this first prospective exploratory study, researchers tested the effectiveness and safety of intravitreal aflibercept (Eylea) (ivA) for retinitis pigmentosa-associated cystoid macular oedema (RP-CMO) at 12 months through mean central macular thickness (CMT) and reported adverse events. Participants in the study were 30 patients (30 eyes). Findings show the safety and acceptability of serial ivA in RP-CMO patients, effectively reducing CMT in 37.9% of patients. All patients who demonstrated anatomical response did so after their first injection. Longer duration of CMO did not adversely affect anti-VEGF response.